Seoul Office Market Enters Structural Reallocation Phase After Record KRW 22.9 Trillion Recovery NEW YORK and SEOUL, Korea, Feb. 3, 2026 /PRNewswire/ -- Newmark Group, Inc. (Nasdaq: NMRK) (Newmark), a ...

As the city and surrounding areas continue to grow, so do the maddening lines of stalled vehicles on some of Puyallup's busiest streets.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Significant respiratory improvements were seen as early as week 4 with dexpramipexole 150mg taken twice daily. Topline data were announced from a phase 3 trial evaluating dexpramipexole as an add-on ...

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival LA JOLLA, CA, Sept. 11, 2025 ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomized, ...

In healthy cells, cyclin D1 is expressed during the G1 phase of the cell cycle, where it activates CDK4 and CDK6. Its dysregulation is a well-established oncogenic driver in numerous human cancers.

Sanofi SA (NASDAQ:SNY) on Tuesday shared progress from its mid- to late-stage respiratory pipeline. The French drug maker reported preliminary results from the TIDE-Asthma phase 2 study of amlitelimab ...

Findings showed treatment with nerandomilast led to a significant improvement in lung function compared with placebo. Topline data were announced from a phase 3 trial evaluating nerandomilast, an oral ...